- |||||||||| Xience (everolimus-eluting stent) / Abbott
Trial completion date, Trial primary completion date: OPEN-ISR: Optimal Treatment for Coronary Drug Eluting Stent In-stent Restenosis (clinicaltrials.gov) - Apr 17, 2024
P=N/A, N=150, Recruiting,
Based on the fact that Beracsurf and Curosurf surfactants did not show significant differences in the treatment outcomes of RDS in preterm neonates, it is suggested that the Iranianmade surfactant, Beracsurf, should be used for the treatment of these neonates due to its cost-effectiveness and availability compared to Curosurf. Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- |||||||||| Alfenta (alfentanil) / Abbott, ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: Effectiveness and safety of remimazolam combined with alfentanil in hysteroscopic examination: A prospective, randomized, single-blind trial. (Pubmed Central) - Apr 16, 2024
In hysteroscopy, the sedative effect of remimazolam is like that of propofol, with 0.25?mg/kg remimazolam showing better safety and efficacy, and less impact on the respiratory and circulatory systems. Additionally, under the influence of alfentanil, the ED50 of remimazolam in hysteroscopy is 0.244?mg/kg, with no severe adverse reactions observed.
- |||||||||| Ganaton (itopride) / Abbott
Journal: The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease. (Pubmed Central) - Apr 4, 2024
No adverse effects were noted. The presented study clearly demonstrates that in patients ineffectively treated with PPIs, the addition of itopride to the therapy for 8 weeks without changing the PPI dose, significantly improves the efficacy of treatment of reflux disease and thus shortens the need for medication usage and reduces the costs of therapy, potential side effects of PPI, improves the patient's quality of life and decreases the frequency of medical appointments.
- |||||||||| Xience (everolimus-eluting stent) / Abbott
Journal: Long-term PCI Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial). (Pubmed Central) - Apr 3, 2024
P=N/A
In conclusion, in the TARGET AC trial, 1 in 3 patients had a major adverse event at 5 years irrespective of CCS or ACS presentation. Long-term, the BP sirolimus-eluting FIREHAWK stent was as safe and effective as the DP everolimus-eluting XIENCE stent across the spectrum of clinical presentations.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Clinical, Journal: Bolus administration of remimazolam was superior to midazolam for deep sedation in elderly patients undergoing diagnostic bronchoscopy: A randomized, double-blind, controlled trial. (Pubmed Central) - Mar 26, 2024
Due to the poor actuality and diverse methodology of included studies and unproportionate data availability for individual drugs, we judged the quality of evidence as low. Bolus administration of remimazolam offers advantages over midazolam for deep sedation in elderly patients undergoing DFB, in terms of a higher success rate of sedation and a lower incidence of extra sleep within 6 hours after procedure, though the safety profiles of both groups were favorable.
- |||||||||| HOKUNALIN patch (tulobuterol) / Maruho, Abbott, Nitto Denko
Journal: Rhamnose-PEG-induced supramolecular helices: Addressing challenges of drug solubility and release efficiency in transdermal patch. (Pubmed Central) - Mar 25, 2024
Pharmacokinetic evaluation demonstrated that the HPR group had >4-fold (Tulobuterol TUL) and 3-fold (Diclofenac DIC) more area under the blood drug concentration curve (AUC) than the commercial TUL and DIC patches in the absence of added excipients and a significantly prolonged mean residence time (MRT) of >4-fold (TUL) and 3-fold (DIC), demonstrating the potential for highly efficacious and prolonged dosing...In summary, HPR enabled a significant simultaneous enhancement of drug loading and drug delivery, which, together with its unique spatial structure, would contribute to the development of TDDS. In addition, the establishment of rhamnose-induced supramolecular helical structures would provide innovative pathways for different drug delivery systems.
- |||||||||| Primaxin (cilastatin/imipenem) / Abbott
Journal: Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients. (Pubmed Central) - Mar 25, 2024
Infection with drug-resistant bacteria is an important factor influencing whether IMI and MEM concentrations reach the target. Furthermore, IMI and MEM concentrations are associated with the clinical outcome, and elevated doses of IMI and MEM should be given to patients who are infected with drug-resistant bacteria.
- |||||||||| Xience (everolimus-eluting stent) / Abbott
Journal: Impact of Incomplete Revascularization After PCI in Left Main Disease: The EXCEL Trial. (Pubmed Central) - Mar 23, 2024
P=N/A
We investigated the clinical impact of complete revascularization in patients with left main coronary artery disease undergoing PCI in the EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization)...Post-PCI untreated high-grade lesions in the LCX (especially the ostial/proximal LCX) drove these outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01205776.
- |||||||||| Xience (everolimus-eluting stent) / Abbott
Retrospective data, Review, Journal: Comparative efficacy of interventional therapies and devices for coronary in-stent restenosis: A systematic review and network meta-analysis of randomized controlled trials. (Pubmed Central) - Mar 18, 2024
Among the PCIs, everolimus-eluting stent was the optimal strategy considering target lesion revascularization (TLR), percent diameter stenosis (%DS), and binary restenosis (BR), and sirolimus-coated balloon was the optimal strategy considering late lumen loss (LLL)...DCB and DES remain the preferred treatment strategies for coronary ISR, considering both the primary clinical outcome (TLR) and the angiographic outcomes (LLL, BR, %DS). Personalized combination interventions including DCB or DES hold promise as a novel potential treatment pattern for coronary ISR.
- |||||||||| Alfenta (alfentanil) / Abbott
Premedication for Neonatal Rapid Sequence Intubation: A Network Meta-analysis (Convention Center Exhibit Hall) - Mar 16, 2024 - Abstract #PAS2024PAS_4512;
Twenty-three RCTs enrolled 931 neonates (Figure 1). Pooled analysis identified that premedication with SAO+SH probably results in improved intubation success (network RR 2.54 [vs. placebo], 95% CI 1.02, 6.29; median rank 1, 95% CI 1-3; very low-certainty; Figure 2).
- |||||||||| Antibiotic Dispensing to U.S. Children, 2019-2023 (Convention Center Exhibit Hall) - Mar 16, 2024 - Abstract #PAS2024PAS_3937;
In June 2023, antibiotic dispensing was 8.9% higher than in June 2019 across all ages, 1.4% higher in those 0-4 years, 29.5% higher in those 5-11 years, and 4.2% lower in those 12-17 years (Fig 1a). In November 2022, amoxicillin dispensing was 0.6% above 2019 levels.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Clinical, Surgery: Clinical Study of Flumazenil Antagonizing Remimazolam on Nausea and Vomiting After Gynecologic Day Surgery. (Pubmed Central) - Mar 15, 2024
Dexamethasone 5 mg, flurbiprofen axetil 50 mg, and droperidol 1 mg were given intravenously before induction of anesthesia in both groups...After the patient fell asleep, mivacurium chloride 0.2mg / kg was injected for 30 seconds and alfentanil 20ug / kg was injected for 30 seconds...The incidence of PONV in the PACU was 5.6% in group F and 8.6% in group C. The difference was not statistically significant (p > 0.05). Flumazenil antagonism of remimazolam increases the incidence of PONV within 24 hours in gynecologic day surgery patients and has no significant effect on the incidence of PONV in the PACU.
- |||||||||| Influvac Tetra (quadrivalent influenza vaccine) / Viatris, Flucelvax (influenza virus trivalent vaccine) / CSL Behring, Influvac (influenza virus surface antigens) / Abbott, Viatris
Journal: Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023-2024. (Pubmed Central) - Mar 13, 2024
This reinforces guideline recommendations to administer long-acting IV antibiotics empirically in the ED upon suspicion of pyelonephritis. Key changes for the 2023-2024 season include: 1) incorporation of updated information/guidance on influenza vaccination in the context of the coronavirus disease 2019 (COVID-19); 2) new recommendations for Flucelvax
- |||||||||| Xience (everolimus-eluting stent) / Abbott
Journal: Influence of Race/Ethnicity and Sex on Coronary Stent Outcomes in Diabetic Patients. (Pubmed Central) - Mar 12, 2024
P=N/A
Using the PLATINUM Diversity and PROMUS Element Plus Post-Approval Pooled Study (N = 4184), we examined the impact of race/ethnicity, sex, and DM on coronary stent outcomes...Aggressive secondary prevention and strict glycemic control are imperative in this cohort, and further research is warranted to elucidate the biologic mechanisms underpinning these observations. NCT02240810 (http://clinicaltrials.gov/).
- |||||||||| Xience (everolimus-eluting stent) / Abbott
Clinical, Retrospective data, Journal: Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials. (Pubmed Central) - Mar 11, 2024
P=N/A, P3
Individual patient data were pooled from 4 trials (SYNTAX [TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries], PRECOMBAT [Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease], NOBLE [PCI vs. CABG in the Treatment of Unprotected Left Main Stenosis], and EXCEL [Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization]) that randomized patients with left main disease to PCI or CABG...Compared with CABG, PCI resulted in no difference in the risk of death, a lower risk of early stroke regardless of diabetes status, and a higher risk of spontaneous MI and repeat coronary revascularization, with larger late absolute excess risks in patients with diabetes. URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01205776, NCT0146651, NCT00422968, and NCT00114972.
- |||||||||| prasugrel / Generic mfg.
Journal, Monotherapy: Prasugrel Monotherapy After Percutaneous Coronary Intervention for (Pubmed Central) - Mar 11, 2024
Prasugrel monotherapy following PCI was safe and feasible in selected low-risk chronic coronary syndrome patients after optimal platinum-chromium everolimus-eluting stent implantation regardless of the ethnic and geographic differences in baseline demographics, procedures, and prasugrel dosage. Randomized controlled trials will be needed to compare P2Y12 inhibitor monotherapy without aspirin with the current standard of care.
- |||||||||| Xience (everolimus-eluting stent) / Abbott
Clinical, Journal, Monotherapy: P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial. (Pubmed Central) - Mar 7, 2024
P=N/A
P2Y12 inhibitor monotherapy after dual antiplatelet therapy (DAPT; a P2Y12 inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for patients undergoing percutaneous coronary intervention (PCI) with a drug-eluting stent...The Short-Term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-Eluting Stent (SHARE) open-label, noninferiority randomized clinical trial was conducted from December 15, 2017, through December 14, 2020...Considering the study population and lower-than-expected event rates, further research is required in other populations. ClinicalTrials.gov Identifier: NCT03447379.
- |||||||||| Primaxin (cilastatin/imipenem) / Abbott
Journal: Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis. (Pubmed Central) - Feb 27, 2024
Our data also suggest antimicrobials that should not be relied upon to treat suspected or documented anthrax meningitis. Furthermore, the protein synthesis inhibitors clindamycin and linezolid can decrease toxin production and may be useful components of combination therapy.
- |||||||||| Xience (everolimus-eluting stent) / Abbott
Journal: One- Versus Three-Month DAPT in Older Patients at High Bleeding Risk Undergoing PCI: Insights From the XIENCE Short DAPT Global Program. (Pubmed Central) - Feb 26, 2024
BARC type 2-5 bleeding was consistently lower with 1- than with 3-month DAPT in patients ?75 years old (7.2% vs 9.4%, adjusted HR 0.66, 95% CI 0.48-0.91) and <75 years old (9.7% vs 11.9%, adjusted HR 0.86, 95% CI 0.57-1.29; interaction p-value 0.737). In conclusion, among HBR patients undergoing PCI, patients older and younger than 75 years of age derived a consistent benefit from 1- as compared with 3-month DAPT in terms of bleeding reduction with no increase in all-cause death or MI at 1 year.
- |||||||||| Primaxin (cilastatin/imipenem) / Abbott, Orpathys (savolitinib) / AstraZeneca, Hutchmed
A Case Report of Severe Lung Cancer Complicated with Severe Infection (San Diego Convention Center, Area J (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6910;
Timely handling of various complications of non-small cell lung cancer with a PS score of ? 2, improving the patient's PS score, and creating conditions for receiving various anti-tumor treatments.
- |||||||||| Primaxin (cilastatin/imipenem) / Abbott
A Case of a Recurrent Pleural Effusion Caused by Mycobacterium Fortuitum (San Diego Convention Center, Area L (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6641;
The patient was discharged with an outpatient regimen comprising Trimethoprim/Sulfamethoxazole 160/800 mg orally every 12 hours and levofloxacin 750 mg orally every 24 hours for 12 months, followed by subsequent culture monitoring...Hirabayashi et al. suggest a treatment plan consisting of eight weeks of imipenem/cilastatin, minocycline, and levofloxacin, followed by four months of maintenance therapy using minocycline and levofloxacin.
- |||||||||| Embolic Stroke and Interatrial Septal Aneurysm Masking the Diagnosis of Granulomatosis With Polyangiitis (San Diego Convention Center, Area H (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5693;
A 70-year-old woman with hypertension and hyperlipidemia presented with generalized weakness, fatigue, rhinorrhea, and sinusitis after treatment with cefdinir and steroids...Patient was started on colchicine, aspirin, and Plavix...She was started on solumedrol and rituximab was added subsequently...While there have been cases of eosinophilic granulomatosis with polyangiitis presenting with ischemic strokes and vision loss, there are few published cases of GPA presenting with such complications. This case shows that GPA can present in atypical fashion with unique sequelae, leading to delay in diagnosis or misdiagnosis, further highlighting the importance of this case.
|
